Early and Late Response and Glucocorticoid-Sparing Effect of Belimumab in Patients with Systemic Lupus Erythematosus with Joint and Skin Manifestations: Results from the Belimumab in Real Life Setting Study-Joint and Skin (BeRLiSS-JS).
Margherita ZenMariele GattoRoberto DepascaleFrancesca RegolaMicaela FrediLaura AndreoliFranco FranceschiniMaria Letizia UrbanGiacomo EmmiFulvia CeccarelliFabrizio ContiAlessandra BortoluzziMarcello GovoniChiara TaniMarta MoscaTania UbialiMaria GerosaEnrica P BozzoloValentina CantiPaolo CardinalettiArmando GabrielliGiacomo TantiElisa GremeseGinevra De MarchiSalvatore De VitaSerena FasanoFrancesco CicciaGiulia PazzolaCarlo SalvaraniSimone NegriniAndrea Di MatteoRossella De AngelisGiovanni OrsoliniMaurizio RossiniPaola FaggioliAntonella LariaMatteo PigaAlberto CauliSalvatore ScarpatoFrancesca Wanda RossiAmato De PaulisEnrico BrunettaAngela CeribelliCarlo Francesco SelmiMarcella PreteVito RacanelliAngelo VaccaElena BartoloniRoberto GerliElisabetta ZanattaMaddalena LarosaFrancesca SacconAndrea DoriaLuca IaccarinoPublished in: Journal of personalized medicine (2023)
Belimumab led to clinical improvement in a significant proportion of patients with joint or skin involvement in a real-life setting and was associated with a glucocorticoid-sparing effect. A significant proportion of patients with a partial response at 6 months achieved remission later on during follow-up.